Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 2/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | CCR5 | P51681 | 6/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2933986 | 0.87 | CYP2D6 (0.54) | CXCR3ALDH1A1MEN1KMT2ACYP2D6 | |
| SCHEMBL1801247 | 0.87 | CYP2D6 (0.54) | CXCR3ALDH1A1MEN1KMT2ACYP2D6 | |
| SCHEMBL2933989 | 0.87 | CYP2D6 (0.54) | CXCR3ALDH1A1MEN1KMT2ACYP2D6 | |
| Hydrochloric Acid SCHEMBL1800675 | 0.87 | CYP2D6 (0.53) | CXCR3ALDH1A1MEN1KMT2ACYP2D6 | |
| SCHEMBL3915181 | 0.82 | LMNA (0.55) | ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL1801540 | 0.81 | CYP2D6 (0.41) | CXCR3SIGMAR1CCR5CHRM3CHRM2 | |
| SCHEMBL2940899 | 0.81 | CYP2D6 (0.41) | CXCR3SIGMAR1CCR5CHRM3CHRM2 | |
| SCHEMBL2940902 | 0.81 | CYP2D6 (0.41) | CXCR3SIGMAR1CCR5CHRM3CHRM2 | |
| SCHEMBL6616737 | 0.80 | CXCR3 (0.69) | CXCR3CCR5 | |
| Hydrochloric Acid SCHEMBL1800899 | 0.80 | CYP2D6 (0.41) | CXCR3SIGMAR1CCR5CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951815-B2 | Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2011-05-31 | — | — | US | disclosed |
| US-20070015784-A1 | Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015784-A1 | Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds | SI, SSTR4, SLC10A2 | CXCR3 4786/4885SIGMAR1 185/4885CCR5 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.